Show summary Hide summary
A large new analysis suggests the most recent shingles vaccine may do more than prevent a painful rash: researchers report a modest decline in cardiovascular events among older adults who received the updated shot. The finding, published Aug. 26 in Nature, raises fresh questions about whether immunization against shingles could also influence heart and stroke risk.
What the study measured
Investigators examined medical records for more than 70,000 U.S. adults aged 60 and older, tracking outcomes for up to seven years after vaccination. Compared with recipients of an earlier vaccine formulation, those who received the newer product experienced a lower overall burden of cardiovascular problems over the follow-up period.
Boxing champions ditch long runs for high-intensity training: new era in fight prep
Czech nationals among victims of Pinedale-area crash: two confirmed dead
Key results included a roughly 9% reduction in combined cardiovascular events, with lower incidences reported for coronary disease, heart failure and atrial fibrillation. The analysis also identified a smaller stroke risk among men who received the updated vaccine.
| Metric | Value |
|---|---|
| Study population | >70,000 U.S. adults, age 60+ |
| Follow-up | Up to 7 years |
| Relative change in cardiovascular burden | ≈9% reduction (new vs. older vaccine) |
| Specific outcomes reduced | Heart disease, heart failure, atrial fibrillation; stroke (men) |
| Published | Nature, Aug. 26, 2026 |
Why this could matter now
Cardiovascular disease remains the leading cause of death worldwide, and shingles affects an estimated one-third of Americans at some point in life. If vaccination can lower heart-related events even modestly at a population level, the public health implications would be significant — but only if the association reflects a true protective effect rather than residual bias.
- The Centers for Disease Control and Prevention recommends the two-dose shingles vaccine starting at age 50; it is known to be about 90% effective at preventing shingles in older adults.
- Reducing infections that stress the body could plausibly lower cardiovascular triggers; alternatively, vaccine-driven changes in immune or cellular activity might confer direct benefits.
- These findings are preliminary and need confirmation in randomized trials and laboratory studies to reveal mechanisms.
Authors’ caution and study limitations
The research team — based in the U.K. — emphasized that their results are observational. They acknowledged potential weaknesses such as incomplete lifestyle and socioeconomic data and the possibility of misclassified diagnoses in medical records.
Importantly, an association in observational data does not prove causation. The authors urged further clinical trials and mechanistic experiments to test whether the vaccine itself produces cardioprotective effects or whether the observed link reflects other differences between groups.
Context and related findings
This is not the first time the shingles shot has been linked to benefits beyond rash prevention. Earlier research has suggested a lower likelihood of developing dementia — and slower progression among some patients — following vaccination, a line of inquiry that ties into wider interest in whether certain herpes viruses contribute to neurological decline.
For readers considering vaccination: the primary indication remains prevention of shingles and its painful complications. Any potential heart-protection effect is promising but unproven, and should not replace established cardiovascular prevention strategies.
Talk with a clinician about whether the shingles vaccine is appropriate for you, especially if you are 50 or older or have other health risks.
